

Outline of Initial Listing Issue

SAWAI GROUP HOLDINGS Co.,Ltd. (hereinafter "the Company"), which is scheduled for listing on Apr. 1, 2021, is the wholly-owning parent company to be established by listed company Sawai Pharmaceutical Co.,Ltd. (Code: 4555, Market Division: 1st Section) via stock transfer. Because the Company has not been established at the time of this document's release, this document contains estimations and predictions regarding the conditions as of Apr. 1, 2021, the day of the company's establishment.

Company Name	SAWAI GROUP HOLDINGS Co.,Ltd.	
Scheduled Listing Date	Apr. 1, 2021	
Market Section	1st Section	
Current Listed Market	N/A	
Name and Title of Representative	SAWAI Kenzo, President, Representative Director	
	Note: As the name and title of representative have yet to be determined, this is tentatively the name and title of representative of Sawai Pharmaceutical Co., Ltd.	
Address of Main Office	5-2-30, Miyahara, Yodogawa-ku, Osaka, 532-0003 Tel. +81-6-6105-5818 (Scheduled to be established on Apr. 1, 2021)	
(Closest Point of Contact)	(Same as above)	
(Contact Details of Wholly-owned Subsidiary)	Sawai Pharmaceutical Co.,Ltd.	Tel. +81-6-6105-5711
Home Page	https://global.sawaigroup holdings (Scheduled to be established on Apr. 1, 2021)	
Date of Incorporation	Apr. 1, 2021	
Description of Business	To manage, provide management support or guidance to domestic and foreign companies engaged in businesses related to medical and healthcare services, such as the manufacture and sale of pharmaceutical products and medical equipment, as well as various businesses incidental or related to the same, through the ownership of shares or equity interests in such companies	
Category of Industry/ Code	Pharmaceutical • 4887 (ISIN JP3323040000)	
Authorized Total No. of Shares to be Issued	77,600,000 shares	
No. of Issued Shares (incl. treasury shares) at the time of Listing	43,791,339 shares	
	Note: If the total number of issued shares of Sawai Pharmaceutical Co.,Ltd. changes before the stock transfer comes into force, the total number of issued shares of SAWAI GROUP HOLDINGS Co.,Ltd. as of Apr. 1, 2021 may change.	
Capital	JPY 10,000,000 thousand	
No. of Shares per Share Unit	100 shares	
Business Year	From Apr. 1 to Mar. 31 of the following year	
General Shareholders Meeting	In June	
Record Date	Mar. 31	
Record Date of Surplus Dividend	Sep. 30 and Mar. 31	

© 2021 Tokyo Stock Exchange, Inc. All rights reserved.

DISCLAIMER: This translation may be used for reference purposes only. This English version is not an official translation of the original Japanese document. In cases where any differences occur between the English version and the original Japanese version, the Japanese version shall prevail. This translation is subject to change without notice. Tokyo Stock Exchange, Inc. and/or Japan Exchange Regulation shall individually or jointly accept no responsibility or liability for damage or loss caused by any error, inaccuracy, misunderstanding, or changes with regard to this translation.

(Reference Translation)

Transfer Agent Sumitomo Mitsui Trust Bank, Limited
Auditor KPMG AZSA LLC

(Appendix) Sawai Pharmaceutical Co.,Ltd. will be delisted on Mar. 30, 2021.

- (Note 1) The company is an initial listing under technical listings prescribed in Rule 208 of the Securities Listing Regulations. In listing examinations of technical listings, Japan Exchange Regulation focuses on whether or not the newly-established company meets certain formal listing criteria at the time of listing. Such listing examinations are different from regular initial listing examinations conducted in detail from perspectives such as corporate continuity and profitability, and soundness of corporate management.
- (Note 2) Documents such as the "Securities Report for Initial Listing Application (Part I)" are available on the JPX website at (<https://www.jpx.co.jp/>) (only in Japanese).

© 2021 Tokyo Stock Exchange, Inc. All rights reserved.

DISCLAIMER: This translation may be used for reference purposes only. This English version is not an official translation of the original Japanese document. In cases where any differences occur between the English version and the original Japanese version, the Japanese version shall prevail. This translation is subject to change without notice. Tokyo Stock Exchange, Inc. and/or Japan Exchange Regulation shall individually or jointly accept no responsibility or liability for damage or loss caused by any error, inaccuracy, misunderstanding, or changes with regard to this translation.